Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/58952
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSupatat Chumnumwaten_US
dc.contributor.authorKong Yien_US
dc.contributor.authorAroonrut Lucksirien_US
dc.contributor.authorWichit Nosoongnoenen_US
dc.contributor.authorBusba Chindavijaken_US
dc.contributor.authorSuvatna Chulavatnatolen_US
dc.contributor.authorAjjima Sarapakdien_US
dc.contributor.authorSurakit Nathisuwanen_US
dc.date.accessioned2018-09-05T04:35:30Z-
dc.date.available2018-09-05T04:35:30Z-
dc.date.issued2018-04-01en_US
dc.identifier.issn17555922en_US
dc.identifier.issn17555914en_US
dc.identifier.other2-s2.0-85043387384en_US
dc.identifier.other10.1111/1755-5922.12315en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85043387384&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/58952-
dc.description.abstract© 2017 John Wiley & Sons Ltd Aim: This study was conducted to compare predictive accuracy of the available pharmacogenetics (PGx)-guided warfarin dosing algorithms derived from Caucasian, Asian, and mixed population to identify a suitable algorithm for Thai population. Methods: Ten warfarin dosing algorithms derived from different population including Caucasian, East Asian, South-East Asian, and mixed races were selected and tested with clinical and genetic data of Thai patients. Comparative performances of these algorithms were tested using mean dose error (MDE) between actual warfarin maintenance dose (AWMD) and predicted dose generated by each dosing algorithm, and percentage of ideal dose prediction (IDP). Sensitivity analysis for predictive accuracy was also conducted by stratifying patients into low (AWMD ≤21 mg/wk), intermediate (AWMD >21 to <49 mg/wk), and high maintenance dose (AWMD ≥49 mg/wk) groups. Results: Data of 165 patients were included for the analyses. Mean actual warfarin dose of the study population was 25.03 ± 10.53 mg/wk. Large variability of MDE, ranging from −12.11 to 11.24 mg/wk, among algorithms was observed. International Warfarin Pharmacogenetics Consortium, Gage et al, and Ohno et al algorithms had comparable performances to Sangviroon et al algorithm, as observed by MDE of <1 mg/wk with percentage of IDP ≥40%. Further sensitivity analyses among patients requiring low and intermediate maintenance doses confirmed such findings with IDP percentage ranging from 37.8% to 59.2%. Among high-dose group, only Ohno et al and Sarapakdi et al algorithms had acceptable performance. Conclusions: Warfarin PGx-guided dosing algorithms derived from large, mixed population performed comparably to Sangviroon et al algorithm. Certain algorithms should be avoided due to significant dose prediction error.en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleComparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai populationen_US
dc.typeJournalen_US
article.title.sourcetitleCardiovascular Therapeuticsen_US
article.volume36en_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.